<DOC>
	<DOCNO>NCT02255968</DOCNO>
	<brief_summary>The primary objective study determine safety tolerability multiple dos orally administer EDP-788 . Secondary objective study describe pharmacokinetics EDP-788 ( metabolite EDP-322 ) multiple dose orally administer drug .</brief_summary>
	<brief_title>Evaluation Safety , Tolerability , Pharmacokinetics Multiple Oral Doses EDP-788</brief_title>
	<detailed_description>Three cohort subject enrol receive either EDP-788 placebo . The dose EDP-788 increase successive cohort . In addition , 4th cohort may enrol , depend clinical finding ( tolerability , safety , pharmacokinetics ) observe first 3 cohort . In cohort , 8 subject receive q12h oral dose regimen EDP-788 ( 6 subject ) placebo ( 2 subject ) . All subject receive multiple dos study drug ( EDP-788 placebo ) .</detailed_description>
	<criteria>Key In good general health BMI 18 32 kg/m2 Women must nonchildbearing potential ( surgically sterilize ) Normal electrocardiogram Willing abstain strenuous physical exercise start 3 day prior admission study clinic 17 19 day postdosing visit Key Hypersensitivity macrolide antibiotic Abnormal laboratory value Gastroenteritis within 1 week study drug administration Use investigational drug within 28 day study drug administration History gastrointestinal surgery may interfere drug absorption Active Hepatitis B , Hepatitis C , HIV infection Use prescription nonprescription drug within 14 day study drug administration Use nicotine within 3 month study drug administration</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Normal Volunteers</keyword>
	<keyword>Safety</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>